Intravitreal bevacizumab treatment for exudative age-related macular degeneration with good visual acuity

Retina

Volumn 32, Issue 9, 2012, Pages 1811-1820

  Axer Siegel, Ruth ^a,b   Bor, Elite ^a,b   Bourla, Dan H ^a   Weinberger, Dov ^a,b   Mimouni, Karin ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

age related macular degeneration; avastin; central macular thickness; intravitreal bevacizumab; optical coherent tomography; visual acuity

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ANTERIOR ISCHEMIC OPTIC NEUROPATHY; ARTICLE; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVITIS; CORNEA EPITHELIUM; DRUG EFFECT; EPIRETINAL MEMBRANE; EXUDATIVE MACULAR DEGENERATION; FEMALE; HERPES ZOSTER OPHTHALMICUS; HUMAN; IRIDOCYCLITIS; MAJOR CLINICAL STUDY; MALE; PUNCTATE KERATITIS; RETINA EXAMINATION; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; TRANSITIONAL BLINDNESS; TREATMENT RESPONSE; VISUAL ACUITY; VITREOUS BODY DETACHMENT; VITREOUS FLOATERS;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; EXUDATES AND TRANSUDATES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RETINA; RETREATMENT; RETROSPECTIVE STUDIES; TONOMETRY, OCULAR; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84866889171     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31825db771     Document Type: Article

References (42)

1. Jonasson F, Arnarsson A, Eiríksdottir G, et al. Prevalence of age-related macular degeneration in old persons: age, gene/environment Susceptibility Reykjavik Study. Ophthalmology 2011;118:825-830.
2. Rein DB, Wittenborn JS, Zhang X, et al; Vision Health Cost-Effectiveness Study Group. Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. Arch Ophthalmol 2009;127:533-540.
3. Rosenfeld PJ, Brown DM, Heier JS, et al, for the MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
4. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007;144:850-857.
5. Brown DM, Michels M, Kaiser PK, et al; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116: 57-65.e5.
6. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58.e1.
7. Schmidt-Erfurth U, Eldem B, Guymer R, et al; EXCITE Study Group. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 2011;118:831-839.
8. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-390.
9. Jonas JB, Libondi T, Ihloff AK, et al. Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. Acta Ophthalmol Scand 2007;85:563-565.
10. Emerson MV, Lauer AK, Flaxel CJ, et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 2007;27:439-444.
11. Cleary CA, Jungkim S, Ravikumar K, et al. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results. Eye (Lond) 2008;22: 82-86.
12. Arias L, Caminal JM, Casas L, et al. A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br J Ophthalmol 2008;92:1636-1641.
13. Fong KC, Kirkpatrick N, Mohamed Q, Johnston RL. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment. Clin Experiment Ophthalmol 2008;36:748-755.
14. Algvere PV, Steén B, Seregard S, Kvanta A. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol 2008;86:482-489.
15. Ehrlich R, Weinberger D, Priel E, Axer-Siegel R. Outcome of bevacizumab (Avastin) injection in patients with age-related macular degeneration and low visual acuity. Retina 2008;28: 1302-1307.
16. Roh MI, Kim HS, Song JH, et al. Concentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed CNV associated with AMD after bevacizumab treatment. Retina 2009;29:523-529.
17. Shah AR, Del Priore LV. Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements. Br J Ophthalmol 2009;93: 1027-1032.
18. Modarres M, Naseripour M, Falavarjani KG, et al. Intravitreal injection of 2.5 mg versus 1.25 mg bevacizumab (Avastin) for treatment of CNV associated with AMD. Retina 2009;29: 319-324.
19. Bashshur ZF, Haddad ZA, Schakal AR, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. Am J Ophthalmol 2009;148:59-65.e1.
20. Leydolt C, Michels S, Prager F, et al. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results. Acta Ophthalmol 2010;88:594-600.
21. Mekjavic PJ, Kraut A, Urbancic M, et al. Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections. Acta Ophthalmol 2011; 89:647-653.
22. Landa G, Amde W, Doshi V, et al. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration. Ophthalmologica 2009;223:370-375.
23. Jyothi S, Chowdhury H, Elagouz M, Sivaprasad S. Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature [review]. Eye (Lond) 2010;24: 816-824.
24. Fong DS, Custis P, Howes J, Hsu JW. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study. Ophthalmology 2010;117: 298-302.
25. Roh MI, Lim SJ, Ahn JM, et al. Concentration of cytokines in age-related macular degeneration after consecutive intravitreal bevacizumab injection. Graefes Arch Clin Exp Ophthalmol 2010;248:635-640.
26. Luu ST, Gray T, Warrier SK, et al. Retrospective study of an as required dosing regimen of intravitreal bevacizumab in neovascular age-related macular degeneration in an Australian population. Clin Experiment Ophthalmol 2010;38:659-663. doi:10.1111/j.1442-9071.2010.02309.x.
27. Arevalo JF, Sánchez JG, Wu L, et al; Pan-American Collaborative Retina Study Group. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study. Ophthalmology 2010;117: 1974-1981.e1.
28. Jonas JB, Tao Y, Schlichtenbrede FC. Intravitreal bevacizumab for exudative age-related macular degeneration in clinical practice. J Ocul Pharmacol Ther 2011; 27:467-470.
29. CATT Research Group; Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular agerelated macular degeneration. N Engl J Med 2011;364:1897- 1908.
30. Brechner RJ, Rosenfeld PJ, Babish JD, Caplan S. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 Medicare fee-for-service part B claims file. Am J Ophthalmol 2011;151:887-895.
31. Wolf-Schnurrbusch UE, Ceklic L, Brinkmann CK, et al. Macular thickness measurements in healthy eyes using six different optical coherence tomography instruments. Invest Ophthalmol Vis Sci 2011;95:1552-1554.
32. Krebs I, Hagen S, Smretschnig E, et al. Conversion of Stratus optical coherence tomography (OCT) retinal thickness to Cirrus OCT values in age-related macular degeneration. Br J Ophthalmol 2011;95:1552-1554.
33. Chopovska Y, Jaeger M, Rambow R, Lorenz B. Comparison of central retinal thickness in healthy children and adults measured with the Heidelberg Spectralis OCT and the zeiss Stratus OCT 3. Ophthalmologica 2011;225:27-36.
34. Williams TA, Blyth CP. Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12. Eye (Lond) 2011;25: 1617-1621.
35. Takahashi M, Sato T, Kishi S. Intravitreal bevacizumab for age-related macular degeneration with good visual acuity. Jpn J Ophthalmol 2010;54:565-570.
36. Rosenfeld PJ, Shapiro H, Tuomi L, et al; MARINA and ANCHOR Study Groups. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology 2011;118:523-530.
37. Singh RP, Fu EX, Smith SD, et al. Predictive factors of visual and anatomical outcome after intravitreal bevacizumab treatment of neovascular age-related macular degeneration: an optical coherence tomography study. Br J Ophthalmol 2009; 93:1353-1358.
38. Tao Y, Libondi T, Jonas JB. Long-term follow-up after multiple intravitreal bevacizumab injections for exudative age-related macular degeneration. J Ocul Pharmacol Ther 2010;26:79-83.
39. Day S, Acquah K, Mruthyunjaya P, et al. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Am J Ophthalmol 2010;54:565-570.
40. Kahook MY, Kimura AE, Wong LJ, et al. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging 2009;40: 293-295.
41. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2011;95:1111-1114.
42. Tseng JJ, Vance SK, Della Torre KE, et al. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular agerelated macular degeneration. J Glaucoma 2012;21:241-247.